Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1907 : TKKK  update : 2021/02/26
CommentHuman cell line derived from intrahepatic bile duct cancer. TKG0456 (Deposited from Tohoku Univ.).
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, Category I and II, depending on the sort of user institutions and the purposes of use.Please use an appropriate MTA(to see).In case of Restriction "a" or "f", please contact RIKEN BRC(cellbank.brc@riken.jp) regarding any kind of for-profit use.
Basic information Depositor Obinata, Masuo
Originator Katayose, Y.
Year of deposit 2004
Original cell TKG0456
Animal human < Mammals
Genus Homo
Species sapiens
Tissue Intrahepatic bile duct
Disease name intraohepatic bile duct carcinoma
Classification cancer
History Cell Resource Center for Biomedical Research, Tohoku University(TKG0456)
Lifespan infinite
Morphology epithelial-like
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Medium and additives DMEM (low glucose) + 10% FBS
Antibiotics Free
Passage method (0.05% trypsin + 0.02% EDTA) or (0.25% trypsin + 0.02% EDTA)
Coating dish type I collagen coated dish
Culture information Passage ratio 1 : 4 split
SC frequency Subculture : once/4 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma (-)
STR(human) OK
Virus (HBV) (-)
Virus (HCV) (-)
Isozyme LD, NP
Images
deposit info
lot info
Reference information Reference 0
User's Publication 13


To topTop
Reference

To topTop
User's Publication
3737  Sakamoto Y, Yamagishi S, Okusaka T, Ojima H.  Synergistic and Pharmacotherapeutic Effects of Gemcitabine and Cisplatin Combined Administration on Biliary Tract Cancer Cell Lines.  Cells  2019  8(9):1026  PubMed ID: 31484399
10759  Sakamoto Y, Yamagishi S, Tanizawa Y, Tajimi M, Okusaka T, Ojima H.  PI3K-mTOR pathway identified as a potential therapeutic target in biliary tract cancer using a newly established patient-derived cell panel assay.  Jpn. J. Clin. Oncol.  2018  48:396-399  PubMed ID: 29474549
10290  Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.  High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.  Mol. Carcinog.  2017  56:2146-2157  PubMed ID: 28467612
3727  Yeung Y, Lau DK, Chionh F, Tran H, Tse JWT, Weickhardt AJ, Nikfarjam M, Scott AM, Tebbutt NC, Mariadason JM  K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.  Mol Oncol  2017  11(9):1130-1142  PubMed ID: 28544747
3735  Saha SK et al  Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.  Cancer Discov  2016  6(7):727-39  PubMed ID: 27231123
7256  Toyota Y, Iwama H, Kato K, Tani J, Katsura A, Miyata M, Fujiwara S, Fujita K, Sakamoto T, Fujimori T, Okura R, Kobayashi K, Tadokoro T, Mimura S, Nomura T, Miyoshi H, Morishita A, Kamada H, Yoneyama H, Okano K, Suzuki Y, Masaki T.  Mechanism of gemcitabine-induced suppression of human cholangiocellular carcinoma cell growth.  Int. J. Oncol.  2015  47:1293-302  PubMed ID: 26252371
3736  Shirota T, Ojima H, Hiraoka N, Shimada K, Rokutan H, Arai Y, Kanai Y, Miyagawa S, Shibata T.  Heat Shock Protein 90 Is a Potential Therapeutic Target in Cholangiocarcinoma.  Mol Cancer Ther.  2015  14(9):1985-93  PubMed ID: 26141945
12541  Soejima Y, Inoue M, Takahashi Y, Uozaki H, Sawabe M, Fukusato T.  ntegrins αvβ6, α6β4 and α3β1 are down-regulated in cholangiolocellular carcinoma but not cholangiocarcinoma  Hepatol Res  2014  44(14):E320-34  PubMed ID: 24552196
3722  Ohashi H, Adachi Y, Yamamoto H, Taniguchi H, Nosho K, Suzuki H, Arimura Y, Imai K, Carbone DP, Shinomura Y.  Insulin-like growth factor receptor expression is associated with aggressive phenotypes and has therapeutic activity in biliary tract cancers.  Cancer Sci  2012  103(2):252-61  PubMed ID: 22044563
7767  Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, Kosuge T, Yoshikawa D, Kono T, Furukawa H, Shibata T.  Prognostic significance of overexpression of c-Met oncoprotein in cholangiocarcinoma.  Br. J. Cancer  2011  105:131-8  PubMed ID: 21673683
7862  Sato J, Kimura T, Saito T, Anazawa T, Kenjo A, Sato Y, Tsuchiya T, Gotoh M.  Gene expression analysis for predicting gemcitabine resistance in human cholangiocarcinoma.  J Hepatobiliary Pancreat Sci  2011  18:700-11  PubMed ID: 21451941
3705  Oka T, Yamamoto H, Sasaki S, Ii M, Hizaki K, Taniguchi H, Adachi Y, Imai K, Shinomura Y.  Overexpression of beta3/gamma2 chains of laminin-5 and MMP7 in biliary cancer.  World J Gastroenterol  2009  15(31):3865-73  PubMed ID: 19701966
6410  Danjoh I, Sone H, Noda N, Iimura E, Nagayoshi M, Saijo K, Hiroyama T, Nakamura Y.  Is parainfluenza virus a threatening virus for human cancer cell lines?  Hum Cell  2009  22(3):81-4  PubMed ID: 19624309



Back Back Return Top Page